期刊文献+
共找到4篇文章
< 1 >
每页显示 20 50 100
A multi-institutional retrospective study of hyperthermic plus intravesical chemotherapy versus intravesical chemotherapy treatment alone in intermediate and high risk nonmuscle-invasive bladder cancer 被引量:5
1
作者 Qiang Ruan degang ding +13 位作者 Bin Wang Chaohong He Xuequn Ren Zhenhua Feng Zhigang Pang Jin Wang Xiangliang Zhang Hongsheng Tang Jiahong Wang Qingjun He Ziying Lei Quanxing Liao Jiali Luo Shuzhong Cui 《Cancer Biology & Medicine》 SCIE CAS CSCD 2021年第1期308-317,共10页
Objective:To compare the efficacy and safety of hyperthermic intravesical chemotherapy(HIVEC)and intravesical chemotherapy(IVEC)in patients with intermediate and high risk nonmuscle-invasive bladder cancer(NMIBC)after... Objective:To compare the efficacy and safety of hyperthermic intravesical chemotherapy(HIVEC)and intravesical chemotherapy(IVEC)in patients with intermediate and high risk nonmuscle-invasive bladder cancer(NMIBC)after transurethral resection.Methods:We included 560 patients diagnosed with primary or recurrent NMIBC between April 2009 and December 2015 at 1 of 6 tertiary centers.We matched 364 intermediate or high risk cases and divided them into 2 groups:the HIVEC+IVEC group[chemohyperthermia(CHT)composed of 3 consecutive sessions followed by intravesical instillation without hyperthermia]and the IVEC group(intravesical instillation without hyperthermia).The data were recorded in the database.The primary endpoint was 2-year recurrence-free survival(RFS)in all NMIBC patients(n=364),whereas the secondary endpoints were the assessment of radical cystectomy(RC)and 5-year overall survival(OS).Results:There was a significant difference in the 2-year RFS between the two groups in all patients(n=364;HIVEC+IVEC:82.42%vs.IVEC:74.18%,P=0.038).Compared with the IVEC group,the HIVEC+IVEC group had a lower incidence of RC(P=0.0274).However,the 5-year OS was the same between the 2 groups(P=0.1434).Adverse events(AEs)occurred in 32.7%of all patients,but none of the events was serious(grades 3–4).No difference in the incidence or severity of AEs between each treatment modality was observed.Conclusions:This retrospective study showed that HIVEC+IVEC had a higher 2-year RFS and a lower incidence of RC than IVEC therapy in intermediate and high risk NMIBC patients.Both treatments were well-tolerated in a similar manner. 展开更多
关键词 Nonmuscle-invasive bladder cancer intravesical chemotherapy HYPERTHERMIA chemohyperthermia retrospective study
下载PDF
Efficacy and safety of LY01005 versus goserelin implant in Chinese patients with prostate cancer: A multicenter, randomized, open-label, phase III, non-inferiority trial 被引量:2
2
作者 Chengyuan Gu Zengjun Wang +59 位作者 Tianxin Lin Zhiyu Liu Weiqing Han Xuhui Zhang Chao Liang Hao Liu Yang Yu Zhenzhou Xu Shuang Liu Jingen Wang Linghua Jia Xin Yao Wenfeng Liao Cheng Fu Zhaohui Tan Guohua He Guoxi Zhu Rui Fan Wenzeng Yang Xin Chen Zhizhong Liu Liqiang Zhong Benkang Shi degang ding Shubo Chen Junli Wei Xudong Yao Ming Chen Zhanpeng Lu Qun Xie Zhiquan Hu Yinhuai Wang Hongqian Guo Tiwu Fan Zhaozhao Liang Peng Chen Wei Wang Tao Xu Chunsheng Li Jinchun Xing Hong Liao Dalin He Zhibin Wu Jiandi Yu Zhongwen Feng Mengxiang Yang Qifeng Dou Quan Zeng Yuanwei Li Xin Gou Guangchen Zhou Xiaofeng Wang Rujian Zhu Zhonghua Zhang Bo Zhang Wanlong Tan Xueling Qu Hongliang Sun Tianyi Gan dingwei Ye 《Chinese Medical Journal》 SCIE CAS CSCD 2023年第10期1207-1215,共9页
Background:LY01005(Goserelin acetate sustained-release microsphere injection)is a modified gonadotropin-releasing hormone(GnRH)agonist injected monthly.This phase III trial study aimed to evaluated the efficacy and sa... Background:LY01005(Goserelin acetate sustained-release microsphere injection)is a modified gonadotropin-releasing hormone(GnRH)agonist injected monthly.This phase III trial study aimed to evaluated the efficacy and safety of LY01005 in Chinese patients with prostate cancer.Methods:We conducted a randomized controlled,open-label,non-inferiority trial across 49 sites in China.This study included 290 patients with prostate cancer who received either LY01005 or goserelin implants every 28 days for three injections.The primary efficacy endpoints were the percentage of patients with testosterone suppression≤50 ng/dL at day 29 and the cumulative probability of testosterone≤50 ng/dL from day 29 to 85.Non-inferiority was prespecified at a margin of-10%.Secondary endpoints included significant castration(≤20 ng/dL),testosterone surge within 72 h following repeated dosing,and changes in luteinizing hormone,follicle-stimulating hormone,and prostate specific antigen levels.Results:On day 29,in the LY01005 and goserelin implant groups,testosterone concentrations fell below medical-castration levels in 99.3%(142/143)and 100%(140/140)of patients,respectively,with a difference of-0.7%(95%confidence interval[CI],-3.9%to 2.0%)between the two groups.The cumulative probabilities of maintaining castration from days 29 to 85 were 99.3%and 97.8%,respectively,with a between-group difference of 1.5%(95%CI,-1.3%to 4.4%).Both results met the criterion for non-inferiority.Secondary endpoints were similar between groups.Both treatments were well-tolerated.LY01005 was associated with fewer injection-site reactions than the goserelin implant(0%vs.1.4%[2/145]).Conclusion:LY01005 is as effective as goserelin implants in reducing testosterone to castration levels,with a similar safety profile.Trial registration:ClinicalTrials.gov,NCT04563936. 展开更多
关键词 Prostatic neoplasms LY01005 Gonadotropin-releasing hormone agonist Efficacy Safety
原文传递
Consensus on safety management of novel hormonal therapy for advanced prostate cancer
3
作者 Sujun Han Shudong Cheng +26 位作者 degang ding Jianming Guo Zhisong He Baiye Jin Zhigang Ji Tianxin Lin Yuanjie Niu Weijun Qin Benkang Shi Jinkai Shao Xi'nan Sheng Qiang Wei Xin Wang Xinghuan Wang Shujie Xia Wanhai Xu Qing Zou Xiongbing Zu Renu Eapen Chi‐Fai Ng Hirotsugu Uemura Hiroji Uemura Cheol Kwak Jae Young Joung Marniza Saad Edmund Chiong Nianzeng Xing 《UroPrecision》 2023年第2期53-71,I0005,共20页
Prostate cancer(PCa)is one of the most prevalent malignant tumors in men,accompanied by high incidence and mortality rates.Novel hormonal therapy(NHT)has emerged as the primary treatment for advanced PCa,providing not... Prostate cancer(PCa)is one of the most prevalent malignant tumors in men,accompanied by high incidence and mortality rates.Novel hormonal therapy(NHT)has emerged as the primary treatment for advanced PCa,providing noticeable clinical benefits.However,the diverse range of adverse events(AEs)associated with NHT may influence both treatment efficacy and patients'quality of life.In light of the latest international clinical research evidence and recommendations from domestic and foreign guidelines,this consensus aims to provide a comprehensive overview of the common AEs experienced during NHT for advanced PCa patients.Additionally,it seeks to develop a hierarchical approach to more efficiently manage AEs,presenting valuable insights for clinical medication and adverse reaction management. 展开更多
关键词 adverse event novel hormonal therapy prostate cancer safety management
原文传递
Detecting prostate cancer and prostatic calcifications using advanced magnetic resonance imaging 被引量:8
4
作者 Shewei Dou Yan Bai +4 位作者 Ankit Shandil degang ding Dapeng Shi E Mark Haacke Meiyun Wang 《Asian Journal of Andrology》 SCIE CAS CSCD 2017年第4期439-443,共5页
Prostate cancer and prostatic calcifications have a high incidence in elderly men. We aimed to investigate the diagnostic capabilities of susceptibility-weighted imaging in detecting prostate cancer and prostatic calc... Prostate cancer and prostatic calcifications have a high incidence in elderly men. We aimed to investigate the diagnostic capabilities of susceptibility-weighted imaging in detecting prostate cancer and prostatic calcifications. A total number of 156 men, including 34 with prostate cancer and 122 with benign prostate were enrolled in this study. Computed tomography, conventional magnetic resonance imaging, diffusion-weighted imaging, and susceptibility-weighted imaging were performed on all the patients. One hundred and twelve prostatic calcifications were detected in 87 patients. The sensitivities and specificities of the conventional magnetic resonance imaging, apparent diffusion coefficient, and susceptibility-filtered phase images in detecting prostate cancer and prostatic calcifications were calculated. McNemar's Chi-square test was used to compare the differences in sensitivities and specificities between the techniques. The results showed that the sensitivity and specificity of susceptibility-filtered phase images in detecting prostatic cancer were greater than that of conventional magnetic resonance imaging and apparent diffusion coefficient (P 〈 0.05). In addition, the sensitivity and specificity of susceptibility-filtered phase images in detecting prostatic calcifications were comparable to that of computed tomography and greater than that of conventional magnetic resonance imaging and apparent diffusion coefficient (P 〈 0.05). Given the high incidence of susceptibility-weighted imaging (SWl) abnormality in prostate cancer, we conclude that susceptibility-weighted imaging is more sensitive and specific than conventional magnetic resonance imaging, diffusion-weighted imaging, and computed tomography in detecting prostate cancer. Furthermore, susceptibility-weighted imaging can identify prostatic calcifications similar to computed tomography, and it is much better than conventional magnetic resonance imaging and diffusion-weighted imaging. 展开更多
关键词 CALCIFICATION computed tomography diffusion-weighted imaging magnetic resonance imaging prostate cancer susceptibility-weighted imaging
原文传递
上一页 1 下一页 到第
使用帮助 返回顶部